Skip to main content
SpringerLink
Log in

Eculizumab for the treatment of atypical hemolytic uremic syndrome recurrence after kidney transplantation associated with complement factor H mutations: a case report with a 5-year follow-up

  • Nephrology - Letter to the editor
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Fremeaux-Bacchi V, Legendre C (2011) New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 7(1):23–35. doi:10.1038/nrneph.2010.155

    Article  PubMed  Google Scholar 

  2. Ponticelli C, Banfi G (2006) Thrombotic microangiopathy after kidney transplantation. Transpl Int 19(10):789–794. doi:10.1111/j.1432-2277.2006.00354.x

    Article  PubMed  Google Scholar 

  3. Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361(17):1676–1687. doi:10.1056/NEJMra0902814

    Article  CAS  PubMed  Google Scholar 

  4. Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A et al (2012) Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 12(12):3337–3354. doi:10.1111/j.1600-6143.2012.04252.x

    Article  CAS  PubMed  Google Scholar 

  5. Le Quintrec M, Lionet A, Kamar N, Karras A, Barbier S, Buchler M et al (2008) Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 8(8):1694–1701. doi:10.1111/j.1600-6143.2008.02297.x

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The Japan Academic Consortium of Kidney Transplantation (JACK) approved by the Institutional Ethics Committee of Tokyo Women’s Medical University (Identifier: 3336-R) is a multicenter observational cohort study of kidney transplant patients in Japan. The case described in this letter is included in the JACK observational cohort.

Author information

Authors and Affiliations

  1. Department of Urology, Kidney Center, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku, Tokyo, 162-8666, Japan

    Masayoshi Okumi, Kazuya Omoto, Hideki Ishida & Kazunari Tanabe

  2. Department of Internal Medicine, Kidney Center, Tokyo Women’s Medical University, Tokyo, Japan

    Kohei Unagami

Authors
  1. Masayoshi Okumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuya Omoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kohei Unagami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hideki Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazunari Tanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masayoshi Okumi.

Ethics declarations

Conflict of interest

All authors declare that there are no competing financial interests.

Informed consent

Informed consent was obtained from the patient in this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okumi, M., Omoto, K., Unagami, K. et al. Eculizumab for the treatment of atypical hemolytic uremic syndrome recurrence after kidney transplantation associated with complement factor H mutations: a case report with a 5-year follow-up. Int Urol Nephrol 48, 817–818 (2016). https://doi.org/10.1007/s11255-016-1234-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-016-1234-y

Keywords

Search

Navigation